Ardelyx (NASDAQ:ARDX) Hits New 52-Week High – Should You Buy?

Ardelyx, Inc. (NASDAQ:ARDX) hit a new 52-week high during trading on Friday . The company traded as high as $7.10 and last traded at $7.00, with a volume of 15572522 shares changing hands. The stock had previously closed at $5.83.

Key Ardelyx News

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Company reported preliminary 2025 product revenue of about $378 million and issued a bullish strategic outlook for 2026 — this is the main fundamental driver supporting the stock’s rally. Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
• Positive Sentiment: Piper Sandler upgraded Ardelyx citing ongoing strength for Ibsrela, which boosted investor confidence and helped extend the share rally. Ardelyx extends rally as Piper Sandler upgrades on Ibsrela strength
• Positive Sentiment: Unusual options activity: investors bought 3,598 call options (about +128% vs. typical daily call volume), indicating short-term bullish positioning by derivatives traders.
• Neutral Sentiment: Media and equity research pieces are re?running valuation and strategy takes after the recent move — these analyses can amplify momentum but are not new company fundamentals. Assessing Ardelyx (ARDX) Valuation After Strong Recent Share Price Momentum
• Neutral Sentiment: Additional commentary examines shifting valuation assumptions and new Ibsrela commercial targets — useful for modelling upside but dependent on execution and duration of uptake. Why The Ardelyx ARDX Story Is Shifting On New Ibsrela Targets And Valuation Assumptions
• Negative Sentiment: Insider selling: Laura A. Williams sold 50,000 shares on Jan. 8 at an average $6.98 (~$349k), reducing her stake by ~12.15% — such disclosure can create short?term headwinds or caution among some investors. Insider Form 4 (Laura A. Williams)

Analyst Ratings Changes

Several research analysts have recently weighed in on ARDX shares. Piper Sandler upgraded Ardelyx from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $10.00 to $16.00 in a report on Thursday. Wedbush downgraded shares of Ardelyx from an “outperform” rating to a “hold” rating in a research note on Tuesday, November 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ardelyx in a research note on Wednesday, October 8th. BTIG Research increased their price target on Ardelyx from $14.00 to $17.00 and gave the stock a “buy” rating in a report on Friday. Finally, Raymond James Financial restated a “strong-buy” rating and issued a $19.00 price objective on shares of Ardelyx in a report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Ardelyx currently has a consensus rating of “Moderate Buy” and a consensus target price of $13.80.

Ardelyx Stock Performance

The firm has a market capitalization of $1.88 billion, a price-to-earnings ratio of -33.65 and a beta of 0.56. The firm has a 50 day moving average price of $5.89 and a 200-day moving average price of $5.50. The company has a debt-to-equity ratio of 1.31, a current ratio of 4.41 and a quick ratio of 4.11.

Ardelyx (NASDAQ:ARDX) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $0.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.06. The company had revenue of $110.33 million during the quarter, compared to the consensus estimate of $100.44 million. Ardelyx had a negative net margin of 14.20% and a negative return on equity of 36.91%. The business’s quarterly revenue was up 14.6% compared to the same quarter last year. As a group, sell-side analysts expect that Ardelyx, Inc. will post -0.18 earnings per share for the current fiscal year.

Insider Transactions at Ardelyx

In related news, insider Mike Kelliher sold 5,560 shares of the stock in a transaction on Friday, November 21st. The stock was sold at an average price of $5.54, for a total transaction of $30,802.40. Following the completion of the sale, the insider directly owned 271,181 shares of the company’s stock, valued at $1,502,342.74. This trade represents a 2.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Elizabeth A. Grammer sold 5,995 shares of the company’s stock in a transaction on Friday, November 21st. The stock was sold at an average price of $5.54, for a total transaction of $33,212.30. Following the transaction, the insider owned 299,895 shares of the company’s stock, valued at approximately $1,661,418.30. The trade was a 1.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 114,868 shares of company stock worth $708,369. 4.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Ardelyx

Several institutional investors have recently made changes to their positions in ARDX. DCF Advisers LLC acquired a new position in shares of Ardelyx during the 2nd quarter worth approximately $39,000. Brighton Jones LLC purchased a new position in Ardelyx during the second quarter worth $40,000. SBI Securities Co. Ltd. raised its holdings in shares of Ardelyx by 147.0% in the third quarter. SBI Securities Co. Ltd. now owns 10,253 shares of the biopharmaceutical company’s stock worth $56,000 after acquiring an additional 6,102 shares during the last quarter. Swiss Life Asset Management Ltd purchased a new stake in shares of Ardelyx in the third quarter valued at $57,000. Finally, State of Wyoming purchased a new stake in shares of Ardelyx in the second quarter valued at $61,000. 58.92% of the stock is currently owned by hedge funds and other institutional investors.

Ardelyx Company Profile

Ardelyx, Inc (NASDAQ: ARDX) is a clinical?stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio?renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.